Turnover: 3.6 billion EUR (2022)

Country: France

BioMerieux is a French company founded in 1897 by Michel Merieux, a pupil of Louis Pasteur, who first developed anti-tetanus serums.

The group employs over 11,000 people worldwide.

BioMérieux is a major player in the in vitro diagnostics market.

The fruit of a family commitment handed down from generation to generation, the company is present in 160 countries, including 43 with a direct presence. Bio Merieux also has 19 industrial sites and 20 R&D centers.

News

BioMérieux boosts capacity at its French plants 27/06/2023

  • BioMérieux investment plan: 300 million euros over five years
  • BioMérieux sales: 3.6 billion euros
  • BioMérieux workforce: 13,800 people
  • Test kit market growth: 10% per year
  • Volume of kits assembled by BioMérieux: 130 to 140 million per year

bioMérieux: end of Covid brings testing champion back down to earth 09/03/2023

  • Family-owned group with 13,000 employees
  • Annual profit reduced from €601 in 2021 to €452 million in 2022, despite sales increasing by 6.3% to €3.6 billion due to the acquisition of US ultra-rapid antibiotic resistance testing company Specific Diagnostics

BioMérieux invests in an ultra-fast antibiotic resistance test. 20/05/2022

  • BioMérieux is the world leader in antibiotic resistance testing, with a 40% market share.
  • The antibiotic resistance testing market represents 10% of bioMérieux sales.
  • Acquisition of California-based Specific Diagnostics
  • Specific Diagnostics' test is sufficiently innovative for bioMérieux to have triggered the acquisition of the company.
  • The California-based company has 82 employees.
  • BioMérieux forecasts sales of $60 million over the next five years,

Financial Data

DUNS: 673620399

Legal Name: BIOMERIEUX SA

Address: , 69280 Marcy-l'Étoile

Number of employees: Entre 2 000 et 4 999 salariés (2020)

Capital: 12 029 370 EUR


Financial Data:

Year 2021 2020 2017 2016 2015
Turnover 1 456 700 000 1 301 100 000 1 137 600 000 1 039 000 000 962 000 000
Gross margin (€) 921 000 000 1 318 300 000 1 564 600 000 -12 700 000 -5 400 000
EBITDA (€) 151 000 000 100 800 000 1 918 000 000 46 300 000 54 600 000
Operating profit (€) 73 500 000 13 000 000 69 700 000 46 300 000 54 600 000
Net profit (€) 205 000 000 23 800 000 109 200 000 69 000 000 75 700 000
Turnover growth rate (%) 12 3,4 9,5 8 -
Ebitda margin rate (%) 10,4 7,7 168,6 4,5 5,7
Operating margin rate (%) 5 1 6,1 4,5 5,7
Working Capital (turnover days) 62,2 76,6 13,8 7,5 13
Working Capital requirements (turnover days) 109,2 109,6 51,6 47,8 56
Net margin (%) 14,1 1,8 9,6 6,7 7,9
Added value / Turnover (%) 37,8 37,8 137,5 75,1 76,6
Wages and social charges (€) 357 700 000 328 000 000 -288 000 000 - -
Salaries / Turnover (%) 24,6 25,2 -25,3 - -

Company Managers:

Position First Name Last Name Age Linkedin
Président du conseil d'administration Alexandre Simon Claude MERIEUX 50
Directeur général Alexandre Simon Claude MERIEUX 50
Directeur général délégué Pierre Christian Claude BOULUD 52
Administrateur Alexandre Simon Claude MERIEUX 50
Administrateur Jean-Luc BELINGARD 75
Administrateur Philippe André Alfred ARCHINARD 64
Administrateur Harold BOËL 59
Administrateur Marie-Hélène DASSAULT 59
Administrateur Agnès POIRIER 69
Administrateur Fanny Gisèle Thérèse DEBREYNE 45
Administrateur Marie-Paule KIENY 68
Administrateur Sylvain Emile Antoine ORENGA 58

Studies mentioning this company

The in vitro diagnostics market - France

Other companies mentioned:

The medical laboratories market - France

Other companies mentioned:

> Besoin de plus d'information sur cette entreprise (SWOT, PESTEL, son marché) ? Demandez à SectorGPT (gratuit)

 

Ask Sector-GPT  

Sector-GPT est la première IA dédiée aux informations sectorielles.